This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	G protein-coupled receptor kinase 3 (GRK3; ADRBK2)	<p>Mouse and human sample studies suggest inhibiting ADRBK2 could help suppress prostate cancer growth and metastasis. In mice orthotopically transplanted with human prostate cancer cells, shRNA against <i>ADRBK2</i> decreased primary tumor growth compared with control shRNA, whereas overexpression of <i>ADRBK2</i> increased primary tumor growth and metastasis to the lung and lymph nodes compared with overexpression of green fluorescent protein. In human prostate tumor samples, elevated ADRBK2 expression correlated with malignancy, visceral metastasis and microvascular proliferation. Next steps include investigating ADRBK2's mechanism of action and identifying small molecule inhibitors of ADRBK2.</p> <p>SciBX 7(6); doi:10.1038/scibx.2014.173 Published online Feb. 13, 2014</p>	Patent status undisclosed; unavailable for licensing	<p>Li, W. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Jan. 13, 2014; doi:10.1073/pnas.1320638111 Contact: Ed Harlow, Harvard Medical School, Boston, Mass. e-mail: eharlow@hms.harvard.edu Contact: Wenliang Li, The University of Texas Health Science Center at Houston, Houston, Texas e-mail: wenliang.li@uth.tmc.edu</p>